1-11 of 11
Kreshnik Zejnullahu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway

Alexis B. Cortot, Claire E. Repellin, Takeshi Shimamura, Marzia Capelletti, Kreshnik Zejnullahu, Dalia Ercan, James G. Christensen, Kwok-Kin Wong, Nathanael S. Gray, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2013) 73 (2): 834–843.
https://doi.org/10.1158/0008-5472.CAN-12-2066
Published: 16 January 2013
View article titled, Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway
Open the PDF for Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway in another window
Includes: Supplementary data
Journal Articles

Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab

Kimio Yonesaka, Isamu Okamoto, Satoh Taroh, Kreshnik Zejnullahu, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Janne, Kazuhiko Nakagawa
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4833.
https://doi.org/10.1158/1538-7445.AM2012-4833
Published: 15 April 2012
View article titled, Abstract 4833: Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutics antibody cetuximab
Journal Articles

Abstract 251: Kinome-wide RNAi screen identification of synthetic lethal interactions in BRAF-mutant melanoma

Kreshnik Zejnullahu, Tim Wagenaar, Michael R. Green
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 251.
https://doi.org/10.1158/1538-7445.AM2011-251
Published: 15 April 2011
View article titled, Abstract 251: Kinome-wide RNAi screen identification of synthetic lethal interactions in BRAF-mutant melanoma
Journal Articles

Abstract #4711: Amplification of EGFR T790M causes resistance to the irreversible EGFR inhibitor PF00299804

Dalia Ercan, Kreshnik Zejnullahu, Yun Xiao, Marzia Capelletti, Andrew Rogers, Charles Lee, James Christensen, Pasi Janne
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4711.
Published: 01 May 2009
View article titled, Abstract #4711: Amplification of EGFR T790M causes resistance to the irreversible EGFR inhibitor PF00299804
Journal Articles

Abstract #3874: MET amplification leads to resistance to the irreversible EGFR inhibitor PF00299804 through selection of a pre-existing MET amplified clone.

Kreshnik Zejnullahu, Young Chul Song, Eugene Lifshits, Luca Toschi, Andrew Rogers, Carly Murphy, Yun Xiao, Charles Lee, James Christensen, Jeffrey Engelman, Pasi Janne
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3874.
Published: 01 May 2009
View article titled, Abstract #3874: MET amplification leads to resistance to the irreversible EGFR inhibitor PF00299804 through selection of a pre-existing MET amplified clone.
Journal Articles

Abstract 4958: Presence of amphiregulin autocrine-loop predicts sensitivity of EGFR wild type cancers to gefitinib and cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Alison J Homes, Bruce E Johnson, Pasi A Janne
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4958.
https://doi.org/10.1158/1538-7445.AM2008-4958
Published: 15 May 2008
View article titled, Abstract 4958: Presence of amphiregulin autocrine-loop predicts sensitivity of <em>EGFR</em> wild type cancers to gefitinib and cetuximab
Journal Articles

Presence of amphiregulin autocrine-loop predicts sensitivity of EGFR wild type cancers to gefitinib and cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Alison Homes, Bruce Johnson, Pasi Janne
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4958.
Published: 01 May 2008
View article titled, Presence of amphiregulin autocrine-loop predicts sensitivity of <em>EGFR</em> wild type cancers to gefitinib and cetuximab
Journal Articles

EML4-ALK fusion gene and sensitivity to an ALK kinase inhibitor in lung cancer

Jussi Koivunen, Craig Mermel, Kreshnik Zejnullahu, Carly Murphy, Alison Holmes, Hwan Geun Choi, Jhingook Kim, Derek Chiang, Jinseon Lee, William Richards, David Sugarbaker, Christopher Ducko, Neal Lindeman, J. Paul Marcoux, Nathanael Gray, Charles Lee, Matthew Meyerson, Pasi Janne
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2373.
Published: 01 May 2008
View article titled, EML4-ALK fusion gene and sensitivity to an ALK kinase inhibitor in lung cancer
Journal Articles

IPI-504, a novel HSP90 inhibitor is effective in EGFR T790M and non-T790M gefitinib-resistant lung cancer cell lines.

Joon Park, Feng Zhao, Kreshnik Zejnullahu, Kelly Slocum, Emmanuel Normant, Jeffrey Engelman, Bruce Johnson, Pasi Janne
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2450.
Published: 01 May 2008
View article titled, IPI-504, a novel HSP90 inhibitor is effective in <em>EGFR</em> T790M and non-T790M gefitinib-resistant lung cancer cell lines.
Journal Articles

Disparate effects of gefitinib and lapatinib on egfr mutant lung cancer

Kreshnik Zejnullahu, Jussi Koivunen, Kimio Yonesaka, Caihong Yun, Jeffrey Swanson, Jeffrey Engelman, Bruce Johnson, Pasi Janne
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 3636.
Published: 01 May 2008
View article titled, Disparate effects of gefitinib and lapatinib on <em>egfr</em> mutant lung cancer
Journal Articles

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, Eugene Lifshits, Andrea J. Gonzales, Takeshi Shimamura, Feng Zhao, Patrick W. Vincent, George N. Naumov, James E. Bradner, Irene W. Althaus, Leena Gandhi, Geoffrey I. Shapiro, James M. Nelson, John V. Heymach, Matthew Meyerson, Kwok-Kin Wong, Pasi A. Jänne
Journal: Cancer Research
Cancer Res (2007) 67 (24): 11924–11932.
https://doi.org/10.1158/0008-5472.CAN-07-1885
Published: 18 December 2007
View article titled, PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <em>EGFR</em> and <em>ERBB2</em> Mutations that Are Resistant to Gefitinib
Open the PDF for PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <em>EGFR</em> and <em>ERBB2</em> Mutations that Are Resistant to Gefitinib in another window
Includes: Supplementary data